Maternal Immune Activation: Implications for Congenital Heart Defects
- PMID: 40175706
- DOI: 10.1007/s12016-025-09049-y
Maternal Immune Activation: Implications for Congenital Heart Defects
Abstract
Congenital heart defects (CHD) are the most common major birth defects and one of the leading causes of death from congenital defects after birth. CHD can arise in pregnancy from the combination of genetic and non-genetic factors. The maternal immune activation (MIA) hypothesis is widely implicated in embryonic neurodevelopmental abnormalities. MIA has been found to be associated with the development of asthma, diabetes mellitus, and other diseases in the offspring. Given the important role of cardiac immune cells and cytokines in embryonic heart development, it is hypothesized that MIA may play a significant role in embryonic heart development. This review aims to stimulate further investigation into the relationship between MIA and CHD and to highlight the gaps in the knowledge. It evaluates the impact of MIA on CHD in the context of pregnancy complications, immune-related diseases, infections, and environmental and lifestyle factors. The review outlines the mechanisms by which immune cells and their secretome indirectly regulate the immuno-microenvironment of the embryonic heart by influencing placental development. Furthermore, the inflammatory cytokines cross the placenta to induce related reactions including oxidative stress in the embryonic heart directly. This review delineates the role of MIA in CHD and underscores the impact of maternal factors, especially immune factors, as well as the embryonic cardiac immuno-microenvironment, on embryonic heart development. This review extends our understanding of the importance of MIA in the pathogenesis of CHD and provides important insights into prenatal prevention and treatment strategies for this congenital condition.
Keywords: Congenital heart defects; Embryonic cardiac immuno-microenvironment; Embryonic heart development; Maternal immune activation; Pregnancy complication.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of Interest: The authors declare no competing interests.
References
-
- Pan M, Li D-Z (2023) Placenta insufficiency and congenital heart defects. American Journal of Obstetrics & Gynecology MFM 5:101070. https://doi.org/10.1016/j.ajogmf.2023.101070 - DOI
-
- Zhao L, Chen L, Yang T et al (2020) Birth prevalence of congenital heart disease in China, 1980–2019: a systematic review and meta-analysis of 617 studies. Eur J Epidemiol 35:631–642. https://doi.org/10.1007/s10654-020-00653-0 - DOI - PubMed - PMC
-
- Su Z, Zou Z, Hay SI et al (2022) Global, regional, and national time trends in mortality for congenital heart disease, 1990–2019: an age-period-cohort analysis for the global burden of disease 2019 study. EClinicalMedicine 43:101249. https://doi.org/10.1016/j.eclinm.2021.101249 - DOI - PubMed - PMC
-
- Zaidi S, Brueckner M (2017) Genetics and genomics of congenital heart disease. Circ Res 120:923–940. https://doi.org/10.1161/CIRCRESAHA.116.309140 - DOI - PubMed - PMC
-
- Feng Y, Cai J, Tong X et al (2018) Non-inheritable risk factors during pregnancy for congenital heart defects in offspring: a matched case-control study. Int J Cardiol 264:45–52. https://doi.org/10.1016/j.ijcard.2018.04.003 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- S202410487728/2024 College Students' Innovative and Entrepreneurial Training Plan Program Project from Huazhong University of Science and Technology
- 2018YFC1004300/the 2024 Key Technology Partnerships Seed Funding Scheme from Huazhong University of Science and Technology and University of Technology Sydney
- 2018YFC1004304/the National Key R&D Program of China
- 2024XBYSKF004/Open Project of the NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China
LinkOut - more resources
Full Text Sources
Medical